Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Conservative management of < 3cm anterior mediastinal lesions in lung cancer screening is safe.

European radiology·2026

Same author

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026

Same author

More harm than good? The UK National Screening Committee's latest review of prostate cancer screening.

BJU international·2026

Same author

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026

Same author

Medicaid Asset Limits And Enrollment Among Older Adults And People With Disabilities.

Health affairs (Project Hope)·2026

Same author

UK National Screening Committee position statement on evidence required for multicancer detection tests.

BMJ (Clinical research ed.)·2026

Same journal

Abstracts from Specialized Centers of Research Excellence (SCORE) on Sex Differences 2025 annual meeting.

BMC proceedings·2026

Same journal

Conference abstracts the 1st UDOM scientific conference on health: healthy lives and well-being for all: opportunities and challenges.

BMC proceedings·2026

Same journal

Entrepreneurship beyond the lab: commercializing your creative outputs.

BMC proceedings·2026

Same journal

The need to strengthen laboratory leadership, systems, and networks to enhance outbreak detection and resilience in Africa: proceedings of a regional workshop.

BMC proceedings·2026

Same journal

Abstracts from the Globesync Community Research and Sustainability 2025 (GlobeCoReS 2025).

BMC proceedings·2026

Same journal

Bauru International Craniofacial Symposium: Comprehensive Care, Policy and Advocacy Proceedings.

BMC proceedings·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Risk stratification in breast screening workshop.

Andrew Anderson¹, Cristina Visintin², Antonis Antoniou³

¹UK NSC secretariat, Sheffield/London, UK. Andrew.Anderson@dhsc.gov.uk.

BMC Proceedings

|October 24, 2024

Summary

This summary is machine-generated.

Risk-stratified breast cancer (BC) screening aims to tailor screening intensity based on individual risk, potentially improving the balance of benefits and harms over current age-based programs. Further research is needed to refine models and infrastructure for effective implementation.

Keywords:

Breast cancer Cost-effectiveness Epidemiology Risk stratification Screening

More Related Videos

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Related Experiment Videos

Last Updated: Jun 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Area of Science:

Oncology
Public Health
Biostatistics

Background:

Current UK breast cancer (BC) screening targets women aged 50-71 to reduce mortality.
High-risk women receive additional screening within the national program.
Growing interest exists in personalizing screening through risk stratification.

Purpose of the Study:

To evaluate risk stratification screening strategies for breast cancer.
To inform the UK National Screening Committee (UK NSC) on potential benefits and harms.
To identify evidence gaps for implementing risk-tailored screening.

Main Methods:

Proceedings of a UK NSC workshop discussing risk prediction and decision-analytic models.
Expert discussions on benefit-harm analysis and economic evaluations of risk-stratified programs.
Review of current expert work and preliminary data.

Main Results:

Experts discussed risk prediction and decision-analytic models for BC screening.
Identified areas for further work include model comparison, risk assessment tools, digital infrastructure, acceptability, screening test choice, and reducing inequalities.
A phased introduction with real-world evidence assessment is suggested for program-wide stratification.

Conclusions:

Risk stratification offers a potential improvement over age-based breast cancer screening.
Further research and careful planning are essential for successful implementation.
Addressing identified gaps is crucial for developing effective, equitable risk-tailored screening programs.